Lyell Immunopharma annual return on equity
2021
2022
2023
2024
2025
Lyell Immunopharma Return on Equity (ROE) Growth & History (LYEL)
Lyell Immunopharma's return on equity was −86.98% for fiscal 2025.
View full Lyell Immunopharma company overviewLyell Immunopharma annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −86.98% | −20.88 pp |
| 2024 | 2024-12-31 | −66.10% | −34.57 pp |
| 2023 | 2023-12-31 | −31.53% | −10.76 pp |
| 2022 | 2022-12-31 | −20.77% | +57.76 pp |
| 2021 | 2021-12-31 | −78.53% | — |
Lyell Immunopharma quarterly return on equity
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −17.64% | −4.20 pp |
| Q1 2026 | 2026-03-31 | −9.26% | +5.26 pp |
| Q4 2025 | 2025-12-31 | −48.75% | −6.73 pp |
| Q3 2025 | 2025-09-30 | −12.37% | −4.24 pp |
| Q2 2025 | 2025-06-30 | −13.43% | −5.60 pp |
| Q1 2025 | 2025-03-31 | −14.51% | −4.87 pp |
| Q4 2024 | 2024-12-31 | −42.02% | −34.19 pp |
| Q3 2024 | 2024-09-30 | −8.13% | −1.04 pp |
| Q2 2024 | 2024-06-30 | −7.83% | +0.57 pp |
| Q1 2024 | 2024-03-31 | −9.64% | −1.36 pp |
| Q4 2023 | 2023-12-31 | −7.83% | −6.81 pp |
| Q3 2023 | 2023-09-30 | −7.09% | +1.23 pp |
| Q2 2023 | 2023-06-30 | −8.40% | −4.25 pp |
| Q1 2023 | 2023-03-31 | −8.28% | −0.76 pp |
| Q4 2022 | 2022-12-31 | −1.02% | +7.72 pp |
| Q3 2022 | 2022-09-30 | −8.32% | −3.46 pp |
| Q2 2022 | 2022-06-30 | −4.15% | +13.01 pp |
| Q1 2022 | 2022-03-31 | −7.53% | — |
| Q4 2021 | 2021-12-31 | −8.74% | — |
| Q3 2021 | 2021-09-30 | −4.87% | — |
| Q2 2021 | 2021-06-30 | −17.16% | — |
Lyell Immunopharma return on equity trends
Between the periods ended 2021-12-31 and 2025-12-31, Lyell Immunopharma's return on equity decreased from −78.53% to −86.98%, a change of −8.45 percentage points. The latest reported quarter, Q2 2026, shows −17.64%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Lyell Immunopharma source filings ↗